| Abstrakt: |
To evaluate the efficacy of Flamigel® RT (Flen Health) in preventing radiation-induced skin reactions (RISR) during proton beam therapy (PBT), a study was conducted with 19 patients using Flamigel® RT. Results showed that by the end of treatment, 52% (n=10) of patients did not experience severe RISR. In children, 55% (n=6) and in adults, 38% (n=3) experienced severe RISR. The majority of the children, 83% (n=5), experienced severe RISR in their last week of treatment, whereas 67% (n=2) of adults did so around the midpoint of their therapy. Flamigel® RT was found to delay and, in some cases, prevent the onset of severe RISR in adults and children undergoing PBT. [ABSTRACT FROM AUTHOR] |
